News & Updates

Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
25 Oct 2022

The use of vedolizumab in the treatment of older patients with inflammatory bowel disease (IBD) appears to not only pose a higher risk of treatment failure but also offer no significant safety advantage when compared with tumour necrosis factor (TNF) antagonists, according to a study.

Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
25 Oct 2022